Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
Most Cited Paper
in Estrogen and related hormone effects
18 Months Post-Publication
Class of 2026
“Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
giredestrant · estrogen receptor-positive breast cancer · HER2-negative breast cancer · advanced breast cancer · acelERA BC study · physician's choice of endocrine monotherapy · fulvestrant · aromatase inhibitor · Progression-free survival · ESR1 mutation · circulating tumor DNA · CDK4/6 inhibitor · GnRH agonist · visceral disease · selective estrogen receptor degrader
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026. https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026. Accessed 2026-07-31. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459